Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Intergalactic Therapeutics Inks $75M Series A

2021-10-07
BOSTON, MA, Intergalactic Therapeutics raises $75 million in Series A funding.
ATP, a leader in life sciences venture capital, today debuted Intergalactic Therapeutics, a non-viral gene therapy platform led by a top management team and funded with $75 million in Series A financing from ATP. Intergalactic's breakthrough approach to non-viral gene therapy deploys two proprietary technologies: 1) C3DNA, covalently closed and circular DNA that does not integrate into the genome or lead to adverse immune reactions, permits large gene cargoes, and relies on a cell-free manufacturing process; and 2) COMET®, a clinically advanced, pulsed electric field focal gene therapy delivery system.

Intergalactic Therapeutics, an ATP company, is revolutionizing gene therapies with a novel non-viral platform comprised of its versatile synthetic and episomal C3DNA (covalently closed and circular DNA) molecules; a customized approach to focal therapeutic delivery using its lead delivery technology, the COMET® pulsed electric field system; and a proprietary cell-free manufacturing process invented to make gene therapy safer and more accessible for patients. With programs in ophthalmology, oncology, respiratory diseases, and expansion areas including CNS, renal, and musculoskeletal, Intergalactic Therapeutics is dedicated to transforming genetic medicine. For more information, visit www.intergalactictx.com.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors